XM không cung cấp dịch vụ cho cư dân của Mỹ.
P
P

Pfizer


Tin tức

Stocks to watch as White House race enters final stretch

UPDATE 1-Stocks to watch as White House race enters final stretch Adds hyperlinks in paragraphs 4 and 32 By Ankika Biswas, Pranav Kashyap Nov 1 (Reuters) - Just days ahead of the Nov. 5 presidential election in the U.S., investors are trying to gauge how stock markets will react as polls and betting platforms point to a tight race between Vice President Kamala Harris and former President Donald Trump.
A
C
G
G
J
M
P
C

Harris vs Trump: Stocks to watch as White House race enters final stretch

Harris vs Trump: Stocks to watch as White House race enters final stretch By Ankika Biswas and Pranav Kashyap Nov 1 (Reuters) - Just days ahead of the Nov. 5 presidential election in the U.S., investors are trying to gauge how stock markets will react as polls and betting platforms point to a tight race between Vice President Kamala Harris and former President Donald Trump.
A
C
G
G
J
M
P
C

Drugmakers Apotex, Heritage to pay $49 mln to resolve states' price-fixing claims

Drugmakers Apotex, Heritage to pay $49 mln to resolve states' price-fixing claims By Mike Scarcella Oct 31 (Reuters) - Generic drugmakers Apotex and Heritage Pharmaceuticals have agreed to pay nearly $50 million to settle claims by Connecticut and other states that accused them of conspiring to artificially inflate prices. Heritage, a subsidiary of India’s Emcure Pharmaceuticals, and Apotex said they will cooperate with the states in continuing litigation against dozens of other drugmakers acc
P
T

Bristol Myers earnings beat expectations, driven by sales of older drugs

UPDATE 1-Bristol Myers earnings beat expectations, driven by sales of older drugs Newer drugs also contribute to earning beat Shares rise to $56.20, highest levels in a year Annual profit forecast raised to 75 to 95 cents a share Adds graphic, shares in paragraph 2, executive comments in paragraph 12-13, analyst comments, paragraphs 9-10 By Michael Erman Oct 31 (Reuters) - Bristol Myers Squibb BMY.N reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of establis
P

Drug wholesalers, others ask US appeals court to revive Lipitor antitrust lawsuits

Drug wholesalers, others ask US appeals court to revive Lipitor antitrust lawsuits By Mike Scarcella Oct 30 (Reuters) - A group of drug wholesalers, retailers, health plans and others have asked a U.S. appeals court to revive their lawsuits accusing pharmaceutical company Ranbaxy of conspiring with Pfizer to delay the release of a generic version of the cholesterol medication Lipitor.
P

Sustainable Finance Newsletter - Nobody cares about your CEO's endorsement anyway

Sustainable Finance Newsletter - Nobody cares about your CEO's endorsement anyway By Ross Kerber Oct 30 (Reuters) - Next week's U.S. presidential election has tested the reflexes of business leaders like none in my memory. Companies have faced direct threats from former Republican President Donald Trump but worry about alienating stakeholders if they speak out, let alone endorse his Democratic rival, Vice President Kamala Harris.
A
P

Street View: Pfizer's long-term growth hinges on product cycle execution

BUZZ-Street View: Pfizer's long-term growth hinges on product cycle execution ** Pfizer PFE.N CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding, after it reported higher-than-expected profit due to strong sales of COVID-19 treatment Paxlo
P

India's Indoco Remedies rises on FDA approval for anti-smoking drug

BUZZ-India's Indoco Remedies rises on FDA approval for anti-smoking drug ** Shares of Indoco Remedies INRM.NS rise as much as 5% to 317.50 rupees ** Co gets U.S. FDA approval for varenicline tablets, which are used to help quit smoking ** INRM last up about 2%, set to snap nine-session losing streak ** Stock still down ~22% so far this year, on tra
P

Pfizer CEO Bourla Says Meeting With Starboard Was Constructive And Cordial

BRIEF-Pfizer CEO Bourla Says Meeting With Starboard Was Constructive And Cordial Oct 29 (Reuters) - Pfizer Inc PFE.N : PFIZER CEO BOURLA SAYS MEETING WITH STARBOARD WAS CONSTRUCTIVE AND CORDIAL - CONF CALL PFIZER CEO BOURLA SAYS SOME SEAGEN PIPELINE ASSETS HAVE POTENTIAL TO BE "MEGABLOCKBUSTERS" PFIZER CEO BOURLA SAYS STARBOARD HAS NOT PRESENTED AN
P

Pfizer Inc reports results for the quarter ended in January 1 - Earnings Summary

Pfizer Inc reports results for the quarter ended in January 1 - Earnings Summary Pfizer Inc PFE.N reported quarterly adjusted earnings of $1.06​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of -17 cents. The mean expectation of sixteen analysts for the quarter was for earnings of 62 cents per share.
P

Futures slip amid earnings deluge, rising Treasury yields

US STOCKS-Futures slip amid earnings deluge, rising Treasury yields For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Alphabet up ahead of earnings after the bell Ford falls, Pfizer rises after results JOLTS job data on tap Futures down: Dow 0.37%, S&P 500 0.18%, Nasdaq 0.07% Updated at 8:20 a.m.
A
G
N
P
U
U
U

U.S. STOCKS McDonald's, Zebra Technologies, Pfizer

BUZZ-U.S. STOCKS ON THE MOVE-McDonald's, Zebra Technologies, Pfizer Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures were little changed on Tuesday as investors prepared for a bevy of corporate results, most notably from Alphabet GOOGL.O to gauge the strength of the technology sector.
A
A
D
G
P
P
V
T
U
R

India's GlaxoSmithKline Pharma posts higher Q2 profit on strong demand

India's GlaxoSmithKline Pharma posts higher Q2 profit on strong demand Oct 29 (Reuters) - India's GlaxoSmithKline Pharmaceuticals GLAX.NS reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and vaccines. The Indian unit of British drugmaker GSK GSK.L said its consolidated profit before tax rose to 3.44 billion rupees ($41 million) in the July-September quarter, from 2.99 billion rupees year ago.
A
G
P

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance

BRIEF-Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance Oct 29 (Reuters) - Pfizer Inc PFE.N : PFIZER REPORTS STRONG THIRD-QUARTER 2024 RESULTS AND RAISES 2024 GUIDANCE PFIZER - APPROXIMATELY $1.5 BILLION EXPECTED BY END OF 2027 FROM FIRST PHASE OF MANUFACTURING OPTIMIZATION PROGRAM PFIZER - AT LEAST $4 BILLION ANTICIPATED BY
P

Pfizer rises after annual forecast raise, Q3 beat

BUZZ-Pfizer rises after annual forecast raise, Q3 beat ** Shares of drugmaker Pfizer PFE.N rise 3.19% to $ 29.78 premarket ** Co reports adj. profit of $1.06 per share vs estimates of 62 cents - LSEG ** Co sees annual profit per share to be between $2.75 and $2.95, compared with its prior forecast of $2.45 to $2.65 per share ** Analysts expect annu
P

Pfizer CEO defends turnaround strategy as activist pressures management

UPDATE 7-Pfizer CEO defends turnaround strategy as activist pressures management Paxlovid sales surge to $2.7 billion, beating expectations Pfizer raises annual revenue forecast for COVID products to $10.5 billion Pfizer management faces pressure from activist hedge fund Starboard Value Pfizer raises full-year profit forecast by 30 cents a share Adds comments from CEO interview in paragraphs 7-8, updates shares By Michael Erman and Bhanvi Satija Oct 29 (Reuters) - Pfizer PFE.N CEO Albert Bourla,
P

Pfizer raises profit forecast after beating third-quarter estimates

Pfizer raises profit forecast after beating third-quarter estimates Oct 29 (Reuters) - U.S. drugmaker Pfizer PFE.N raised its full-year profit forecast after it beat Wall Street estimates for third-quarter earnings on Tuesday, powered by strong demand for its cancer treatments and some older drugs. On an adjusted basis, the company earned $1.06 per share, compared with the average analyst estimate of 62 cents per share, according to data compiled by LSEG.
P

Election-agitated Treasuries meet megacap earnings

MORNING BID AMERICAS-Election-agitated Treasuries meet megacap earnings A look at the day ahead in U.S. and global markets from Mike Dolan Even as public borrowing estimates were shaved on Monday, U.S. Treasury yields continue to probe three-month highs as markets lean toward a win for Donald Trump in next week's election and a possible clean sweep in Congress for his Republican party.
E
G
G
H
I
M
M
P
P
U
V
A
J
U
U
U
U
E
E
R
S
D
B

Futures tread water amid earnings deluge; Ford falls

US STOCKS-Futures tread water amid earnings deluge; Ford falls For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Futures up: Dow 0.02%, S&P 500 0.02%, Nasdaq 0.05% Oct 29 (Reuters) - U.S. stock index futures were little changed on Tuesday as investors prepared for a bevy of corporate results, most notably from Alphabet GOOGL.O to gauge the strength of the technology sector.
G
M
N
P
T
U
U
U

What to Watch in the Day Ahead - Tuesday, October 29

What to Watch in the Day Ahead - Tuesday, October 29 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Alphabet will report results for its third quarter.
G
I
J
M
P
P
V
A
R
D



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.